Clinical trials can be an exciting way to address a medical problem. Participation allows patients to receive medication that might otherwise not be available through any means, and the office visits and any blood tests or other diagnostic procedures associated with study are provided free of charge. In some cases there may also be a patient stipend for the time it takes out of your schedule and for transportation assistance. The research at NervePro consists of Phase III studies. This type of study involves medications or devices that have already been shown to be safe in preliminary Phase I and II studies and to have some degree of effectiveness in Phase II studies. Phase III studies test the medication on a larger number of participants with the expectation that the next step would be approval by the FDA if safety and efficacy are established.
Unlike many clinical trial centers, NervePro is an active neurology practice, and patients are under no pressure to participate in research if they chose not to. Those patients that have been involved in trials are allowed to stay in the practice as regular patients once their participation is completed if Dr. Cleeremans is a provider on their insurance plan.
The research division of NervePro Medical Corporation has successfully performed studies in Headache, Painful neuropathy, Seizures, Alzheimer’s and multi-infarct dementias, myofascial pain, fibromyalgia, low back pain, insomnia, multiple sclerosis, Parkinson’s Disease, TIAs, and strokes. If you are interested, call the office and see what programs may be of interest to you.
Ongoing Clinical Trials:
Most approved medications have only a modest beneficial effect, it will be several years before new ones are available outside of a clinical trial, during which time those afflicted are steadily getting worse. At NervePro, we have participated in phase III clinical trials for early to moderate Alzheimer’s dementia for 15 years. Our current studies are closed to new enrollment.
We do not presently have an active migraine study. We have participated in two targeting the CGRP receptor in the past three years that have been promising and hopefully will be available in the market early in 2017.